Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective.
This review displays the AGO Ovarian Cancer Study Group approach towards evaluation of improvement options in first-line therapy of advanced ovarian cancer. Prospectively randomized phase III trials evaluating the addition of newer drugs to standards carboplatin-paclitaxol (TC) as well as pilot trials evaluating new treatment modalities like anti-idiotype CA 125 antibodies or epidermal growth factor receptor (EGFR) modulation are presented.
du Bois
A
A
Department of Gynecology and Gynecologic Oncology, Dr Horst-Schmidt-Kliniken, Wiesbaden, Germany. dubois.hsk-Wiesbaden@uumail.de
Pfisterer
J
J
Meier
W
W
Wagner
U
U
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D012107:Research Design; D019772:Topotecan / Q000008:administration & dosage; D000093542:Gemcitabine
D003841:Deoxycytidine; D015251:Epirubicin; D019772:Topotecan; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine